Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Newron Pharmaceuticals SpA ( (CH:NWRN) ) is now available.
Newron Pharmaceuticals has announced significant progress in its pivotal Phase III development program for Evenamide, an add-on therapy for treatment-resistant schizophrenia. The company has received regulatory approvals and initiated patient recruitment for its ENIGMA-TRS studies, highlighting strategic partnerships in Asia to expand its market reach. These developments position Evenamide as a potential blockbuster drug, addressing a critical need for new schizophrenia treatments and enhancing Newron’s industry standing.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF8.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company based in Milan, Italy, focused on developing novel therapies for patients with central and peripheral nervous system disorders. The company is particularly involved in the development of Evenamide, a drug aimed at treating treatment-resistant schizophrenia.
Average Trading Volume: 56,365
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF178.7M
See more data about NWRN stock on TipRanks’ Stock Analysis page.